|
注册号: Registration number: |
ChiCTR2600121876 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-07 08:38:43 |
|
注册时间: Date of Registration: |
2026-04-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
应用肠道菌群移植治疗精神类药物相关便秘的临床疗效及作用 |
|
Public title: |
Clinical Efficacy and Mechanism of Fecal Microbiota Transplantation in the Treatment of Psychotropic Drug-Related Constipation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
应用肠道菌群移植治疗精神类药物相关便秘的临床疗效及作用 |
|
Scientific title: |
Clinical Efficacy and Mechanism of Fecal Microbiota Transplantation in the Treatment of Psychotropic Drug-Related Constipation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
耿焱 |
研究负责人: |
耿焱 |
|
Applicant: |
Yan Geng |
Study leader: |
Yan Geng |
|
申请注册联系人电话: Applicant telephone: |
+86 771 287 0093 |
研究负责人电话:
Study leader's |
+86 186 4894 5667 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
drggyn@163.com |
研究负责人电子邮件: Study leader's E-mail: |
drggyn@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广西壮族自治区南宁市青秀区植物路52号 |
研究负责人通讯地址: |
中国广西壮族自治区南宁市青秀区植物路52号 |
|
Applicant address: |
No. 52, Plant Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China |
Study leader's address: |
No. 52, Plant Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国人民解放军联勤保障部队第九二三医院 |
||
|
Applicant's institution: |
923 Hospital of the Joint Service Support Force of the Chinese People's Liberation Army |
||
|
研究负责人所在单位: |
中国人民解放军联勤保障部队第九二三医院 |
||
|
Affiliation of the Leader: |
923 Hospital of the Joint Service Support Force of the Chinese People's Liberation Army |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
923LL-KY2026-011-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军联勤保障部队第九二三医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the 923rd Hospital of the Chinese People's Liberation Army Joint Logistics Support Force |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-01 00:00:00 | ||
|
伦理委员会联系人: |
李晓宇 |
||
|
Contact Name of the ethic committee: |
Li Xiaoyu |
||
|
伦理委员会联系地址: |
中国广西壮族自治区南宁市青秀区植物路52号 |
||
|
Contact Address of the ethic committee: |
No. 52, Plant Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 771 287 0228 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国人民解放军联勤保障部队第九二三医院 |
||||||||||||||||||||||
|
Primary sponsor: |
923 Hospital of the Joint Service Support Force of the Chinese People's Liberation Army |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国广西壮族自治区南宁市青秀区植物路52号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 52, Plant Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
联勤保障部队优质专科学科经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Funds for high-quality specialized disciplines of the Joint Logistics Support Force |
||||||||||||||||||||||
|
研究疾病: |
消化系统胃肠疾病 |
||||||||||||||||||||||
|
Target disease: |
Gastrointestinal diseases of the digestive system |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1. 评估FMT联合常规治疗对精神类药物相关便秘的临床疗效 2. 评估FMT联合常规治疗方案的安全性与耐受性 3. 探索FMT治疗精神类药物相关便秘的作用机制 |
||||||||||||||||||||||
|
Objectives of Study: |
1.To evaluate the clinical efficacy of fecal microbiota transplantation (FMT) combined with conventional therapy in the treatment of psychotropic drug-related constipation. 2.To assess the safety and tolerability of FMT combined with conventional therapy. 3.To explore the mechanism of action of FMT in the treatment of psychotropic drug-related constipation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.肠道器质性疾病(肠梗阻、肿瘤、炎症性肠病等)所致便秘; 2.有FMT禁忌证(严重免疫缺陷、严重感染、对FMT胶囊过敏); 3.合并严重肝肾功能不全、心血管疾病; 4.近3个月接受过益生菌、抗生素或微生态制剂治疗; 5.妊娠或哺乳期女性; 6.无法配合完成随访评估。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Constipation caused by organic intestinal diseases (intestinal obstruction, tumor, inflammatory bowel disease, etc.). 2.Presence of contraindications to fecal microbiota transplantation (FMT), including severe immunodeficiency, severe infection, and hypersensitivity to FMT capsules. 3.Complicated with severe hepatic or renal insufficiency and cardiovascular diseases. 4.Received treatment with probiotics, antibiotics or microecological preparations within the past 3 months. 5.Pregnant or lactating women. 6.Unable to cooperate and complete follow-up assessments. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-04-10 00:00:00至 To 2029-04-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-11 00:00:00 至 To 2029-01-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用随机对照设计,由统计人员采用随机数字表法生成随机序列。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study adopted a randomized controlled design, and the statistical personnel used the random number table method to generate a random sequence. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
患者和疗效评估人员 |
|
Blinding: |
Patients and outcome assessors |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |